Protective role of nrf2 in renal disease

Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2...

Descripción completa

Detalles Bibliográficos
Autores: Guerrero-Hue, Melania, Rayego-Mateos, Sandra, Vázquez-Carballo, Cristina, Palomino-Antolín, Alejandra, García-Caballero, Cristina, Opazo-Ríos, Lucas, Morgado-Pascual, José Luis, Herencia, Carmen, Mas, Sebastián, Ortiz Arduán, Alberto, Rubio-Navarro, Alfonso, Egea, Javier, Villalba, José Manuel, Egido de los Ríos, Jesús, Moreno, Juan Antonio
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/699586
Acceso en línea:http://hdl.handle.net/10486/699586
https://dx.doi.org/10.3390/antiox10010039
Access Level:acceso abierto
Palabra clave:Acute kidney injury
Inflammatory response
Nrf2
Oxidative stress
Renal disease
Medicina
Descripción
Sumario:Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role in protection against oxidative stress and regulation of the inflammatory response. Consequently, the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseases